Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
160M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
136M
-
Shares change
-
+1.83M
-
Total reported value, excl. options
-
$973M
-
Value change
-
+$19M
-
Put/Call ratio
-
0.29
-
Number of buys
-
106
-
Number of sells
-
-70
-
Price
-
$7.18
Significant Holders of Cogent Biosciences, Inc. - Common Stock, $0.001 par value (COGT) as of Q2 2025
224 filings reported holding COGT - Cogent Biosciences, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Cogent Biosciences, Inc. - Common Stock, $0.001 par value (COGT) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 136M shares
of 160M outstanding shares and own 84.5% of the company stock.
Largest 10 shareholders include FMR LLC (17.1M shares), Paradigm Biocapital Advisors LP (10.4M shares), BlackRock, Inc. (8.63M shares), Kynam Capital Management, LP (8.49M shares), TCG Crossover Management, LLC (6.96M shares), VANGUARD GROUP INC (6.52M shares), Fairmount Funds Management LLC (6.23M shares), Point72 Asset Management, L.P. (4.91M shares), VR ADVISER, LLC (4.76M shares), and UBS Group AG (3.52M shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.